Skip to Main Content

Paper Details

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Blood
26
2022
Author NameAffiliation
Brandon Hayes-LattinCenter for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University
Richard T MaziarzCenter for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University
  • 1 - 2

Datasets

Release 1.2